Serum tumor markers for pancreatic cancer: the dawn of new era?
Okusaka
Takuji
T
Yamada
Tesshi
T
Maekawa
Masato
M
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D018395:CA-19-9 Antigen / Q000097:blood; D019175:DNA Methylation; D004273:DNA, Neoplasm / Q000032:analysis; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000069347:Erlotinib Hydrochloride; D006801:Humans; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D040901:Proteomics; D011799:Quinazolines / Q000627:therapeutic use; D012680:Sensitivity and Specificity; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D014408:Biomarkers, Tumor; D018395:CA-19-9 Antigen; D004273:DNA, Neoplasm; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D003841:Deoxycytidine; D000069347:Erlotinib Hydrochloride; D000093542:Gemcitabine